Analysis Group Researchers Present at Major Health Care Conference

September 19, 2016

Researchers from Analysis Group's Health Care practice will deliver 14 poster presentations at the Academy of Managed Care Pharmacy's (AMCP's) Nexus 2016 conference, which will be held October 3-6 in the Gaylord National Hotel located in Maryland's National Harbor area. Three of the posters supported by Analysis Group researchers received medals.

Gold medal
“Cardiac Resynchronization Therapy and Adherence to Heart Failure Regimens,” coauthored by an Analysis Group team led by Managing Principals Mei Sheng Duh and Patrick Lefebvre.

Bronze medals
“Predictors and Clinical Outcomes of Treatment Intensification in Type 2 Diabetes Patients Uncontrolled on Two or More Oral Anti-Diabetic Agents in a Real-World Setting,” coauthored by an Analysis Group team led by Managing Principal Mei Sheng Duh.

“Real-world Persistence with Fingolimod for the Treatment of Multiple Sclerosis: A Systematic Review and Meta-analysis,” coauthored by an Analysis Group team led by Managing Principal Eric Wu and Vice President James Signorovitch.

Additional poster presentations
“Reductions in Concomitant Antidiabetic Medication Use and Hemoglobin A1C Level Associated with Liraglutide Initiation for the Treatment of Type 2 Diabetes,” coauthored by an Analysis Group team led by Managing Principal Mei Sheng Duh, Senior Economist François Laliberté , and Senior Analyst Nora McCormick.

“Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients with Primary Immunodeficiency Disease Switching to Hizentra” and “Comparison of Real-World Prophylactic Dosing of Recombinant Coagulation Factor IX to Prescribing Information-Recommended Doses,” coauthored by an Analysis Group team led by Managing Principal Mei Sheng Duh, Vice President Brian Ellman, and Senior Analyst Rachel Bhak.

“Diagnosis-level Drivers and Trajectory of Excess Costs Prior to and After Diagnosis of Opioid Abuse,” coauthored by an Analysis Group team led by Principal Howard Birnbaum and Vice President Noam Kirson.

“Consideration of Concomitant Medication Use in Selection of FDA-approved Drugs Indicated for Prostate Cancer,” coauthored by an Analysis Group team led by Managing Principal Patrick Lefebvre and other Analysis Group researchers.

“Quality Measure Attainment Among Adults Diagnosed with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics,” “Medicaid Spending and Healthcare Resource Use in Patients with Schizophrenia Using Second-Generation Long-Acting Injectable versus Oral Atypical Antipsychotics,” and “Adherence, Persistence, and Inpatient Utilization Among Adult Schizophrenia Patients Using Once-monthly versus Twice-monthly Long-acting Antipsychotics,” coauthored by an Analysis Group team led by Managing Principal Patrick Lefebvre, Senior Economist Marie-Hélène Lafeuille, and other Analysis Group researchers.

“Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide,” coauthored by an Analysis Group team led by Managing Principal Patrick Lefebvre.

“The Economic Burden of Hyperkalemia Among Patients with Chronic Kidney Disease and/or Heart Failure,” coauthored by an Analysis Group team led by Managing Principal Eric Wu and Senior Analyst Cheryl Xiang.

“The Prevalence of Hyperkalemia in the United States,” coauthored by an Analysis Group team led by Managing Principal Eric Wu and Senior Analyst Evangeline McDonald.

Read more about the AMCP Nexus 2016 Conference